Email this article Efficiency of ursodesoxycholicacid in cholesterosis of the gallbladder
- Authors: Ilchenko AA1, Orlova Y.N1
-
Affiliations:
- Issue: Vol 78, No 2 (2003)
- Pages: 35-38
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29310
- ID: 29310
Cite item
Full Text
Abstract
Aim. To study efficacy of ursodesoxycholic acid (UA) drugs in the treatment of polypous and polyporeticular cholesterosis of the gallbladder (CGB), including combination with biliary sludge, with reference to terms of the treatment.
Material and methods. A contraction function of the gallbladder was studied ultrasonically in 74 CGB patients treated with UA drugs. The treatment lasted from 1 month to 1.5 years. A response (complete or partial dilution of cholesterol polyps) was recorded in 71.6% patients. Therapy was less effective if the gallbladder contained biliary sludge, heterogeneous bile and suspension, dense bile. The lytic therapy effect improved with treatment duration. Complete dissolving of cholesterol polyps was achieved after at least 10-month treatment. The treatment also brought about a marked choleretic effect and an increased ejection fraction of the gallbladder. Conclusion. UA drugs can be used in the treatment of CGB.
Material and methods. A contraction function of the gallbladder was studied ultrasonically in 74 CGB patients treated with UA drugs. The treatment lasted from 1 month to 1.5 years. A response (complete or partial dilution of cholesterol polyps) was recorded in 71.6% patients. Therapy was less effective if the gallbladder contained biliary sludge, heterogeneous bile and suspension, dense bile. The lytic therapy effect improved with treatment duration. Complete dissolving of cholesterol polyps was achieved after at least 10-month treatment. The treatment also brought about a marked choleretic effect and an increased ejection fraction of the gallbladder. Conclusion. UA drugs can be used in the treatment of CGB.
Keywords
References
- Свиридов А. В. Холестероз желчного пузыря (патогенез, лечение). Автореф. дис. ... канд. мед. наук. М.: 2001.
- Чернышев А. Л.. Макашов В. А., Тарасов К. М., Куликов А. Г. Литолитическая терапия в дифференциальной диагностике полипозной формы холестероза и полипов желчного пузыря. Рос. гастроэнтеролог, журн. 2000; 2: 127-128.
- Иваиченкова Р. А., Измайлова Т. Ф., Метельская В. А. и др. Холестероз желчного пузыря. Клиника, диагностика, лечение. Клин. мед. 1997; 5: 46-51.
- Brogna A., Bucceri A. М., Faulisi R. et al. Gallbladder polyps and cholestcrolosis are not risk factors for gallstoune development. Gut 1999; 45(suppl. 5): A225.
- Орлова Ю. Н., Гуляев В. В. Ультрасонография в диагностике холестероза желчного пузыря. Рос. гастроэнтеролог. журн. 200; 4: 137-138.
- Трофимов В. М., Калашников С. А., Рылло А. Г. Клиникоморфологические особенности холестероза желчного пузыря и возможности его диагностики у больных желчнокаменной болезнью. Рос. журн. гастроэнтерол., гепатол.. колопроктол. 1994; 4: 40-47.
- Вихрова Т. В. Роль литолитической терапии в лечении заболеваний желчевыводяших путей. Рос. гастроэнтеролог. журн. 1998; 4: 86-87.
- Осипенко М. Ф., Бикбулатова Е. А., Пешкова Л. Ю. и др. Опыт использования урсосана для дифференциальной диагностики полиповидных образований желчного пузыря. Там же. 2001; 2; 104-108.
- Ильченко А. А. Классификация желчнокаменной болезни. Эксперим. и клин, гастроэнтерол. 2002; 1: 131 - 132.
Supplementary files
